ERBB2 and breast cancer: After combining trastuzumab and pyrotinib to treat HER2-positive breast cancer cells, cell survival was higher in the group with excess PPARG expression (Supplementary figure 1E), suggesting that PPARG may enhance resistance to combination therapy with dual-target drugs in HER2-positive breast cancer cells.